The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Kiniksa transitions from survival risk to growth, targeting dominance in the pericarditis market with robust cash flow and expanding margins. KNSA's Arcalyst drives revenue growth, with 2026 guidance ...
Earnings Call Insights: Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2025 Sanj Patel, CEO & Chairman of the Board, stated that "Year-to-date, in 2025, we've continued to execute and ...
LONDON, April 08, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (KNSA) (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for ...
Hosted on MSN
Kiniksa outlines $900M–$920M 2026 ARCALYST revenue guidance as market penetration deepens
Earnings Call Insights: Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Sanj Patel, CEO, stated that "ARCALYST revenue continues to grow, driven by the expanding adoption of IL-1 alpha and ...
Kiniksa Pharmaceuticals reported a 56% year-over-year revenue increase, driven by ARCALYST sales. The company raised its full-year 2026 revenue guidance to $930 million - $945 million. Net income ...
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) presented its fourth quarter and full year 2025 financial results on February 24, 2026, showcasing a significant transition to profitability driven by robust ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results